

Edited by Jarkko Rautio


 WILEY-VCH

Prodrugs and Targeted Delivery

Towards Better ADME Properties

Volume 47

Series Editors:
R. Mannhold,
H. Kubinyi,
G. Folkers



Edited by
Jarkko Rautio

Prodrugs and Targeted Delivery

Towards Better ADME Properties



**WILEY-
VCH**

WILEY-VCH Verlag GmbH & Co. KGaA

Series Editors

Prof. Dr. Raimund Mannhold

Molecular Drug Research Group
Heinrich-Heine-Universität
Universitätsstrasse 1
40225 Düsseldorf
Germany
mannhold@uni-duesseldorf.de

Prof. Dr. Hugo Kubinyi

Donnersbergstrasse 9
67256 Weisenheim am Sand
Germany
kubinyi@t-online.de

Prof. Dr. Gerd Folkers

Collegium Helveticum
STW/ETH Zurich
8092 Zurich
Switzerland
folkers@collegium.ethz.ch

Volume Editor

Prof. Dr. Jarkko Rautio

University of Eastern Finland
School of Pharmacy
Yliopistonranta 1
70211 Kuopio
Finland

Cover Description

Prodrugs are bioreversible derivatives of drug molecules that can address ADME issues ("backbone") and must undergo an enzymatic and/or chemical transformation *in vivo* to release the pharmacologically active parent drug. A representative prodrug is oseltamivir (Tamiflu®). (Laskowski anatomy taken with courtesy of the U.S. National Library of Medicine)

All books published by Wiley-VCH are carefully produced. Nevertheless, authors, editors, and publisher do not warrant the information contained in these books, including this book, to be free of errors. Readers are advised to keep in mind that statements, data, illustrations, procedural details or other items may inadvertently be inaccurate.

Library of Congress Card No.: applied for

British Library Cataloguing-in-Publication Data

A catalogue record for this book is available from the British Library.

Bibliographic information published by the Deutsche Nationalbibliothek

The Deutsche Nationalbibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data are available on the Internet at <http://dnb.d-nb.de>.

© 2011 WILEY-VCH Verlag & Co. KGaA,
Boschstr. 12, 69469 Weinheim, Germany

All rights reserved (including those of translation into other languages). No part of this book may be reproduced in any form – by photoprinting, microfilm, or any other means – nor transmitted or translated into a machine language without written permission from the publishers. Registered names, trademarks, etc. used in this book, even when not specifically marked as such, are not to be considered unprotected by law.

Typesetting Thomson Digital, Noida, India

Printing and Binding betz-druck GmbH, Darmstadt

Cover Design Grafik-Design Schulz, Fußgönheim

Printed in the Federal Republic of Germany
Printed on acid-free paper

ISBN: 978-3-527-32603-7

List of Contributors

Jane P.F. Bai

US Food and Drug Administration
Center for Drug Evaluation and
Research
Office of Translational Science
Office of Clinical Pharmacology
10903 New Hampshire, Ave.
Silver Spring
MD 20993
USA

Eyal H. Barash

Barash Law LLC
3000 Kent Avenue
West Lafayette
IN 47906
USA

Ujjwal Chakraborty

University of Kentucky
Department of Chemistry
Lexington
KY 40536-0082
USA

Peter A. Crooks

University of Kentucky
College of Pharmacy
Department of Pharmaceutical Sciences
Lexington
KY 40536-0082
USA

Harpreet K. Dhooper

University of Kentucky
Department of Chemistry
Lexington
KY 40536-0082
USA

Paul W. Erhardt

The University of Toledo College of
Pharmacy
Center for Drug Design and
Development
Toledo
OH
USA

Ripal Gaudana

University of Missouri-Kansas City
School of Pharmacy
Division of Pharmaceutical Sciences
Kansas City
MO
USA

Victor R. Guarino

Bristol-Myers Squibb
Pharmaceutical Candidate
Optimization
Princeton
NJ 08543
USA

Douglas Hedley

Institute of Cancer Research
CRC Centre for Cancer Therapeutics
15 Cotswold Road
Sutton
Surrey SM2 5NG
UK

Kristiina Huttunen

University of Eastern Finland
School of Pharmacy
Yliopistonranta 1
FI-70211 Kuopio
Finland

Jwala Jwala

University of Missouri-Kansas City
School of Pharmacy
Division of Pharmaceutical Sciences
Kansas City
MO
USA

Deep Kwatra

University of Missouri-Kansas City
School of Pharmacy
Division of Pharmaceutical Sciences
Kansas City
MO
USA

Krista Laine

University of Eastern Finland
School of Pharmacy
Yliopistonranta 1
FI-70211 Kuopio
Finland

Lawrence L. Lesko

US Food and Drug Administration
Center for Drug Evaluation and
Research
Office of Translational Science
Office of Clinical Pharmacology
10903 New Hampshire, Ave.
Silver Spring
MD 20993
USA

Paul R. Lockman

Texas Tech University Health Sciences
Center
Department of Pharmaceutical Sciences
1406 Coulter
Amarillo
TX 79106
USA

Susruta Majumdar

Memorial Sloan
Kettering Cancer Center
Laboratory of Chemistry, Pharmacology,
and Neuroscience
1275 York Avenue
New York
NY 10021
USA

Ashim K. Mitra

University of Missouri-Kansas City
School of Pharmacy
Division of Pharmaceutical Sciences
Kansas City
MO
USA

Majid Y. Moridani

Texas Tech University
Health Sciences Center
Amarillo
TX 79106
USA

Gabriel Negoita-Giras

Institute of Cancer Research
CRC Centre for Cancer Therapeutics
15 Cotswold Road
Sutton
Surrey SM2 5NG
UK

Dan Niculescu-Duvaz

Institute of Cancer Research
CRC Centre for Cancer Therapeutics
15 Cotswold Road
Sutton
Surrey SM2 5NG
UK

John P. O'Donnell

Pfizer Global Research and
Development
Department of Antibacterials Research
Eastern Point Road
Groton
CT 06340
USA

Mike Pacanowski

US Food and Drug Administration
Center for Drug Evaluation and
Research
Office of Translational Science
Office of Clinical Pharmacology
10903 New Hampshire, Ave.
Silver Spring
MD 20993
USA

Atiqur Rahman

US Food and Drug Administration
Center for Drug Evaluation and
Research
Office of Translational Science
Office of Clinical Pharmacology
10903 New Hampshire, Ave.
Silver Spring
MD 20993
USA

Jarkko Rautio

University of Eastern Finland
School of Pharmacy
Yliopistonranta 1
FI-70211 Kuopio
Finland

Michael D. Reese

The University of Toledo College of
Pharmacy
Center for Drug Design and
Development
Toledo
OH
USA

Kenneth Sloan

University of Florida
Department of Medicinal Chemistry
1600 SW Archer Road P6-20
Gainesville
FL 32610
USA

Quentin R. Smith

Texas Tech University
Health Sciences Center
Department of Pharmaceutical Sciences
1406 Coulter
Amarillo
TX 79106
USA

Caroline J. Springer

Institute of Cancer Research
CRC Centre for Cancer Therapeutics
15 Cotswold Road
Sutton
Surrey SM2 5NG
UK

Ravi Vaishya

University of Missouri-Kansas City
School of Pharmacy
Division of Pharmaceutical Sciences
Kansas City
MO
USA

Scott C. Wasdo

University of Florida
Department of Anesthesiology
1600 SW Archer Road M5-16
Gainesville
FL 32610
USA

Mark S. Warren

XenoPort, Inc.
3410 Central Expressway
Santa Clara
CA 95051
USA

Preface

Historically, biological screening of new compounds was performed in animals. Application by the enteral route automatically provided a first overview on bioavailability and biological half-life. Nowadays, lead structure search and optimization are dominated by *in vitro* screening systems. Correspondingly, problems in compound liberation, oral absorption, organ distribution, metabolism, and excretion (LADME) are often observed at a relatively late stage. The problems may already result either from inappropriate lead structure selection or from unidirectional affinity optimization, without sufficient consideration for solubility, permeation properties, and metabolic stability. However, there are many options to rescue a preclinical candidate with such problems. Liberation can be enhanced by increasing the solubility via the formation of polar derivatives, for example, phosphates, reduction of carbonyl to hydroxyl groups, or introduction of polar, most often basic residues, where they do not negatively interfere with binding. Absorption can be enhanced by making the compound more lipophilic in first line by the conversion of acids into esters. Distribution can be influenced by using transporters, for example, for the blood–brain barrier penetration of L-DOPA, or by designing compounds that are preferentially metabolized in a certain organ or tumor, for example, omeprazole or capecitabine. Metabolism can be easily controlled by avoiding or introducing metabolically labile groups.

Prodrugs are inactive or less active drug analogues or derivatives that have better physicochemical or pharmacokinetic properties than their parent drugs. They are more or less specifically metabolized to the active form of the drug. There are manifold reasons for the development of a prodrug. In most cases, prodrugs are designed for a drug that is not sufficiently bioavailable. Other reasons are that the drug does not permeate the blood–brain barrier, the drug has poor solubility or taste, the drug has no sufficient chemical stability, or the drug has no sufficient organ or cell specificity. Soft drugs (sometimes also called antedugs) are drugs with very short half-life or without systemic activity. Some esters of corticosteroid carboxylic acids are topically active; after dermal absorption, they are metabolically degraded to inactive analogues, in this manner avoiding systemic side effects. Targeted drugs are drugs or prodrugs that exert their biological action only in certain organs or cells.

We are very grateful to Jarkko Rautio, who assembled a team of leading experts to discuss all these concepts. In a comprehensive manner, strategies are presented to rescue a drug candidate with insufficient ADME properties. For this purpose, the book is well suited both for all practitioners in medicinal chemistry and for graduate students who want to learn about rational concepts of lead structure optimization. We are also grateful to Frank Weinreich and Nicola Oberbeckmann-Winter for their ongoing support and enthusiasm for our book series, *Methods and Principles in Medicinal Chemistry*, of which this book is another highlight.

October 2010

Raimund Mannhold, Düsseldorf
Hugo Kubinyi, Weisenheim am Sand
Gerd Folkers, Zurich

A Personal Foreword

The prodrug concept, as first introduced by Adrian Albert in the 1950s, defines a prodrug as a pharmacologically inactive agent that undergoes an enzymatic and/or chemical transformation *in vivo* to a therapeutically active drug. Prodrug strategies have traditionally been used to address ADMET (absorption, distribution, metabolism, excretion, and toxicity) properties and risks of marketed drugs or as a tool in late-stage problem solving for drug development candidates. However, prodrugs are now increasingly being integrated into early drug discovery. Indeed, the successful application of prodrug strategies over the past two decades has significantly increased the percentage of drugs approved as prodrugs to an eye-catching 10%. In addition, the percentage of prodrugs among the world's top-selling drugs is particularly high, including blockbusters such as all the proton pump inhibitor "prazoles," the antiplatelet agent clopidogrel, and the hypercholesterolemia drugs simvastatin and fenofibrate, to name a few.

The success of prodrugs can also be seen in the literature. Books, book chapters, and numerous research and review articles have been published in recent years, with the compilation of the prodrug two-volume book in 2007 by AAPS Press/Springer and edited by Professor Valentino Stella *et al.* certainly providing the most comprehensive overview of early and current prodrug strategies. So why do we need a new book on prodrugs so soon? The idea of this new prodrug book was mulled over by several prodrug enthusiasts, and it soon became obvious that there are topics that are not really addressed in the existing works. Moreover, I think the more perspectives we can explore on strategies suitable for a prodrug approach, or when they should not be pursued, the better off we will be scientifically. Thus, with some trepidation regarding content, especially trying to avoid extensive redundancy, the task was indeed found worth rewarding and invigorating.

This volume of *Methods and Principles in Medicinal Chemistry* contains various strategies for prodrug design and highlights many examples of prodrugs that either have been launched or are undergoing experimental assessment. Part One begins with a historical overview and is followed by approaches of prodrug design and the concepts of prodrug patentability. Part Two focuses on the ADMET issues that can be addressed by prodrugs, ranging from permeability and solubility to targeting. In Part

Three, the emphasis is on codrugs, which consist of two active drugs incorporated into a single chemical entity, and soft drugs, which in contrast to prodrugs are designed to undergo inactivation after their biotransformation. Both prodrugs and soft drugs rely upon biotransformation to dictate their course of activation and are worth discussing in the same context. Part Four is devoted to preclinical and clinical considerations for prodrugs providing a discovery screening strategy for evaluation of prodrugs and pharmacogenetic focus for prodrugs.

I want to express my sincere gratitude to all authors for their excellent efforts and cooperation. It has been a pleasure for me to be involved with all of these high-profile prodrug enthusiasts. I also want to acknowledge the people at Wiley-VCH, namely, Dr Nicola Oberbeckmann-Winter for her tireless support in the production of this book and Dr Hugo Kubinyi for his valuable advice on its content. I truly hope that this book will stimulate multidisciplinary teams of medicinal chemists, biologists, and other scientists in drug design and development process to consider a prodrug approach as a rational tool in drug discovery that will ultimately lead to better drugs.

October 2010

Jarkko Rautio, Kuopio

Contents

List of Contributors	XVII
Preface	XXI
A Personal Foreword	XXIII

Part One Prodrug Design and Intellectual Property 1

1	Prodrug Strategies in Drug Design	3
	<i>Jarkko Rautio</i>	
1.1	Prodrug Concept	3
1.2	Basics of Prodrug Design	4
1.3	Rationale for Prodrug Design	5
1.3.1	Overcoming Formulation and Administration Problems	6
1.3.2	Overcoming Absorption Barriers	8
1.3.3	Overcoming Distribution Problems	9
1.3.4	Overcoming Metabolism and Excretion Problems	10
1.3.5	Overcoming Toxicity Problems	10
1.3.6	Life Cycle Management	13
1.4	History of Prodrug Design	14
1.5	Recently Marketed Prodrugs	17
1.5.1	Prodrug Prevalence	17
1.5.2	Recent Prodrug Approvals	17
1.6	Concluding Remarks	25
	References	26
2	The Molecular Design of Prodrugs by Functional Group	31
	<i>Victor R. Guarino</i>	
2.1	Introduction	31
2.2	The Prodrug Concept and Basics of Design	32
2.3	Common Functional Group Approaches in Prodrug Design	34

2.3.1	Aliphatic and Aromatic Alcohols	34
2.3.1.1	Phosphate Monoesters	35
2.3.1.2	Simple Acyl Esters	37
2.3.1.3	Amino Acid Esters	38
2.3.1.4	Other Ester-Based Approaches	39
2.3.2	Carboxylic Acids	40
2.3.2.1	Alkyl Esters	41
2.3.2.2	Aminoalkyl Esters	42
2.3.2.3	Spacer Groups to Alleviate Steric Hindrance	42
2.3.3	Imides, Amides, and Other NH Acids	43
2.3.3.1	Imide-Type NH Acids	44
2.3.3.2	Amide-Type NH Acids	44
2.3.3.3	Sulfonamide NH Acids	48
2.3.4	Phosphates, Phosphonates, and Phosphinates	49
2.3.4.1	Simple Alkyl and Aryl Esters	49
2.3.4.2	Acyloxyalkyl and Alkoxyalkoxyalkyl Esters	50
2.3.4.3	Aryl Phospho(n/r)amidates and Phospho(n/r)diamides	51
2.3.4.4	HepDirect Technology	53
2.3.5	Amines and Benzamidines	53
2.3.5.1	N-Acyloxyalkoxycarbonyl Prodrugs	54
2.3.5.2	N-Mannich Bases	55
2.3.5.3	N-Acyloxyalkyl and N-Phosphoryloxyalkyl Prodrugs of Tertiary Amines	55
2.3.5.4	N-Hydroxy and Other Modifications for Benzamidines	56
2.4	Conclusions	56
	References	57
3	Intellectual Property Primer on Pharmaceutical Patents with a Special Emphasis on Prodrugs and Metabolites	61
	<i>Eyal H. Barash</i>	
3.1	Introduction	61
3.2	Patents and FDA Approval Process	61
3.3	Obtaining a Patent	65
3.3.1	Utility	66
3.3.2	Novelty	67
3.3.3	Nonobviousness	71
3.4	Conclusion	78
Part Two	Prodrugs Addressing ADMET Issues	79
4	Increasing Lipophilicity for Oral Drug Delivery	81
	<i>Majid Y. Moridani</i>	
4.1	Introduction	81
4.2	pK_a , Degree of Ionization, Partition Coefficient, and Distribution Coefficient	81

4.3	Prodrug Strategies to Enhance Lipid Solubility	85
4.4	Prodrug Examples for Antibiotics	87
4.4.1	Bacampicillin	87
4.4.2	Carindacillin	88
4.4.3	Cefditoren Pivoxil	89
4.4.4	Cefuroxime Axetil	90
4.4.5	Cefpodoxime Proxetil	91
4.5	Antiviral Related Prodrugs	92
4.5.1	Oseltamivir	92
4.5.2	Famciclovir	92
4.5.3	Adefovir Dipivoxil	93
4.5.4	Tenofovir Disoproxil	94
4.6	Cardiovascular Related Prodrugs	95
4.6.1	Enalapril	95
4.6.2	Fosinopril	96
4.6.3	Olmesartan Medoxomil	97
4.7	Lipophilic Prodrugs of Benzamidine Drugs	98
4.7.1	Ximelagatran	98
4.7.2	Dabigatran Etxilate	99
4.8	Miscellaneous Examples	100
4.8.1	Capecitabine	100
4.8.2	Mycophenolate Mofetil	101
4.8.3	Misoprostol	102
4.8.4	Additional Examples	102
4.9	Summary and Conclusion	104
	References	106
5	Modulating Solubility Through Prodrugs for Oral and IV Drug Delivery	111
	<i>Victor R. Guarino</i>	
5.1	Introduction	111
5.2	Basics of Solubility and Oral/IV Drug Delivery	112
5.2.1	Some Basic Fundamentals of Solubility	112
5.2.2	Some General Comments on IV Drug Delivery	114
5.2.3	Some General Comments on Oral Drug Delivery	116
5.3	Prodrug Applications for Enhanced Aqueous Solubility	117
5.3.1	Prodrug Concept	117
5.3.2	Examples of Prodrugs to Enhance Aqueous Solubility for IV Administration	118
5.3.2.1	Fosphenytoin	118
5.3.2.2	Fospropofol	119
5.3.2.3	Parecoxib	120
5.3.2.4	Irinotecan	120
5.3.3	Prodrugs to Enhance Aqueous Solubility for Oral Administration	121
5.3.3.1	Fosamprenavir	121

5.3.3.2	Valganciclovir	122
5.4	Challenges with Solubilizing Prodrugs of Insoluble Drugs	123
5.4.1	Challenges with Solubilizing Prodrug Strategies for IV Administration	123
5.4.2	Challenges with Solubilizing Prodrug Strategies for Oral Administration	124
5.5	Additional Applications of Prodrugs for Modulating Solubility	125
5.5.1	Alleviating pH-Dependent Oral Bioavailability of Weakly Basic Drugs	126
5.5.2	Aligning pH-Solubility and pH-Stability Relationships for IV Products	126
5.5.3	Modulating Solubility in Negative Direction	127
5.6	Parallel Exploration of Analogues and Prodrugs in Drug Discovery (Commentary)	128
5.7	Conclusions	129
	References	129

6 Prodrugs Designed to Target Transporters for Oral Drug Delivery 133

Mark S. Warren and Jarkko Rautio

6.1	Introduction	133
6.2	Serendipity: An Actively Transported Prodrug	133
6.3	Requirements for Actively Transported Prodrugs	135
6.4	Peptide Transporters: PEPT1 and PEPT2	135
6.5	Monocarboxylate Transporters	140
6.6	Bile Acid Transporters	143
6.7	Conclusions	147
	References	147

7 Topical and Transdermal Delivery Using Prodrugs: Mechanism of Enhancement 153

Kenneth Sloan, Scott C. Wasdo, and Susruta Majumdar

7.1	Introduction	153
7.2	Arrangement of Water in the Stratum Corneum	155
7.3	A New Model for Diffusion Through the Stratum Corneum: The Biphasic Solubility Model	156
7.4	Equations for Quantifying Effects of Solubility on Diffusion Through the Stratum Corneum	158
7.4.1	The Roberts–Sloan Equation When the Vehicle is Water	159
7.4.2	The Roberts–Sloan Equation When the Vehicle is a Lipid	160
7.4.3	The Series/Parallel Equation When the Vehicle is a Lipid	161
7.5	Design of Prodrugs for Topical and Transdermal Delivery Based on the Biphasic Solubility Model	162
7.5.1	5-Fluorouracil Prodrugs	164
7.5.1.1	N-Acyl 5-FU Prodrugs	165
7.5.1.2	N-Soft Alkyl 5-FU Prodrugs	166

7.5.2	Acetaminophen (APAP) Prodrugs	167
7.5.2.1	O-Acyl APAP Prodrugs	168
7.5.2.2	O-Soft Alkyl APAP Prodrugs	170
7.5.3	S-Soft Alkyl Prodrugs of 6-Mercaptopurine	170
7.5.3.1	Effect of Vehicles on Topical and Transdermal Delivery	171
7.6	Comparison of Human and Mouse Skin Experiments	172
7.7	Summary	174
	References	175
8	Ocular Delivery Using Prodrugs	181
	<i>Deep Kwatra, Ravi Vaishya, Ripal Gaudana, Jwala Jwala, and Ashim K. Mitra</i>	
8.1	Introduction	181
8.2	Criteria for an Ideal Ophthalmic Prodrug	181
8.3	Anatomy and Physiology of the Eye	182
8.3.1	Anterior Chamber	183
8.3.2	Posterior Chamber	183
8.4	Barriers to Ocular Drug Delivery	184
8.4.1	Tear Film	184
8.4.2	Corneal Epithelium	184
8.4.3	Aqueous Humor and BAB	184
8.4.4	Conjunctiva	184
8.4.5	Blood–Retinal Barrier	185
8.5	Influx and Efflux Transporters on the Eye	185
8.6	Transporter-Targeted Prodrug Approach	186
8.6.1	Acyclovir	186
8.6.2	Ganciclovir	188
8.6.3	Quinidine	188
8.7	Drug Disposition in Ocular Delivery	189
8.8	Effect of Physiochemical Factors on Drug Disposition in Eye	190
8.9	Prodrug Strategy to Improve Ocular Bioavailability (Nontransporter-Targeted Approach)	192
8.9.1	Epinephrine	192
8.9.2	Phenylephrine	192
8.9.3	Pilocarpine	193
8.9.4	Timolol	195
8.9.5	Prostaglandin F _{2α}	197
8.10	Recent Patents and Marketed Ocular Prodrugs	198
8.11	Novel Formulation Approaches for Sustained Delivery of Prodrugs	201
8.12	Conclusion	201
	References	202
9	Reducing Presystemic Drug Metabolism	207
	<i>Majid Y. Moridani</i>	
9.1	Introduction	207

9.2	Presystemic Metabolic Barriers	209
9.2.1	Esterases	209
9.2.2	Cytochrome P450 Enzymes	212
9.2.3	Phase II Drug Metabolizing Enzymes	214
9.2.4	Peptidases	215
9.2.5	Other Oxidative Metabolizing Enzymes	216
9.3	Prodrug Approaches to Reduce Presystemic Drug Metabolism	217
9.4	Targeting Colon	220
9.5	Targeting Lymphatic Route	221
9.6	Conclusion	225
	References	226

10 Enzyme-Activated Prodrug Strategies for Site-Selective Drug Delivery 231

Krista Laine and Kristiina Huttunen

10.1	Introduction	231
10.2	General Requirements for Enzyme-Activated Targeted Prodrug Strategy	232
10.3	Examples of Targeted Prodrug Strategies	232
10.3.1	Tumor-Selective Prodrugs	232
10.3.1.1	Prodrugs Activated by Hypoxia-Associated Reductive Enzymes	233
10.3.1.2	Prodrugs Activated by Glutathione S-Transferase	236
10.3.1.3	Prodrugs Activated by Thymidine Phosphorylase	237
10.3.2	Organ-Selective Prodrugs	239
10.3.2.1	Liver-Targeted Prodrugs	239
10.3.2.2	Kidney-Targeted Prodrugs	242
10.3.2.3	Colon-Targeted Prodrugs	243
10.3.3	Virus-Selective Prodrugs	244
10.4	Summary	245
	References	246

11 Prodrug Approaches for Central Nervous System Delivery 253

Quentin R. Smith and Paul R. Lockman

11.1	Blood–Brain Barrier in CNS Drug Development	253
11.2	Prodrug Strategies	255
11.3	Prodrug Strategies Based Upon BBB Nutrient Transporters	257
11.4	Prodrug Strategies Based Upon BBB Receptors	263
11.5	CNS Prodrug Summary	264
	References	266

12 Directed Enzyme Prodrug Therapies 271

Dan Niculescu-Duvaz, Gabriel Negoita-Giras, Ion Niculescu-Duvaz, Douglas Hedley, and Caroline J. Springer

12.1	Introduction	271
12.2	Theoretical Background of DEPT	271